Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
Myriad Genetics (NASDAQ: MYGN) has scheduled its third quarter 2024 earnings conference call for November 7, 2024, at 4:30 pm ET, with results to be released after market close. Management will provide financial overview and business updates during the call. Additionally, the company announced participation in two upcoming investor healthcare conferences: The Guggenheim Inaugural Global Healthcare Conference on November 13, featuring CEO Paul J. Diaz, and The 6th Annual Wolfe Research Healthcare Conference on November 20, featuring CFO Scott Leffler and COO Sam Raha.
Myriad Genetics (NASDAQ: MYGN) ha programmato la sua call di earnings del terzo trimestre 2024 per il 7 novembre 2024, alle 16:30 ET, con i risultati che saranno pubblicati dopo la chiusura del mercato. La direzione fornirà un'overview finanziaria e aggiornamenti sull'attività durante la call. Inoltre, l'azienda ha annunciato la sua partecipazione a due prossime conferenze sanitarie per investitori: la Guggenheim Inaugural Global Healthcare Conference del 13 novembre, con il CEO Paul J. Diaz, e la 6th Annual Wolfe Research Healthcare Conference del 20 novembre, con il CFO Scott Leffler e il COO Sam Raha.
Myriad Genetics (NASDAQ: MYGN) ha programado su llamada de ganancias del tercer trimestre de 2024 para el 7 de noviembre de 2024, a las 4:30 pm ET, con resultados que se publicarán después del cierre del mercado. La dirección proporcionará una visión general financiera y actualizaciones de la empresa durante la llamada. Además, la compañía anunció su participación en dos próximas conferencias de salud para inversionistas: la Guggenheim Inaugural Global Healthcare Conference el 13 de noviembre, con el CEO Paul J. Diaz, y la 6th Annual Wolfe Research Healthcare Conference el 20 de noviembre, con el CFO Scott Leffler y el COO Sam Raha.
마이리어드 제네틱스 (NASDAQ: MYGN)는 2024년 3분기 실적 컨퍼런스 콜을 2024년 11월 7일 오후 4시 30분 ET에 개최할 예정이며, 시장 종료 후 결과가 발표될 것입니다. 경영진은 콜 동안 재무 개요와 사업 업데이트를 제공할 것입니다. 또한, 회사는 두 개의 다가오는 투자자 헬스케어 회의에 참여한다고 발표했습니다: 구겐하임 첫 글로벌 헬스케어 회의가 11월 13일 열리며, CEO 폴 J. 디아즈가 참석하고, 제6회 울프 리서치 헬스케어 회의가 11월 20일 열리며, CFO 스콧 레플러와 COO 샘 라하가 참석합니다.
Myriad Genetics (NASDAQ: MYGN) a programmé sa conférence téléphonique sur les résultats du troisième trimestre 2024 pour le 7 novembre 2024 à 16h30 ET, avec les résultats publiés après la clôture du marché. La direction fournira un aperçu financier et des mises à jour commerciales lors de l'appel. De plus, la société a annoncé sa participation à deux prochaines conférences de santé pour investisseurs : la Guggenheim Inaugural Global Healthcare Conference le 13 novembre, avec le PDG Paul J. Diaz, et la 6th Annual Wolfe Research Healthcare Conference le 20 novembre, avec le CFO Scott Leffler et le COO Sam Raha.
Myriad Genetics (NASDAQ: MYGN) hat seine Ergebnis-Konferenzschaltung für das dritte Quartal 2024 für den 7. November 2024 um 16:30 Uhr ET angesetzt, die Ergebnisse werden nach Börsenschluss veröffentlicht. Das Management wird während des Calls einen finanziellen Überblick und Unternehmensupdates geben. Darüber hinaus hat das Unternehmen die Teilnahme an zwei bevorstehenden Investoren-Gesundheitskonferenzen angekündigt: der Guggenheim Inaugural Global Healthcare Conference am 13. November, mit CEO Paul J. Diaz, und der 6th Annual Wolfe Research Healthcare Conference am 20. November, mit CFO Scott Leffler und COO Sam Raha.
- None.
- None.
Management will also participate in two upcoming investor healthcare conferences
SALT LAKE CITY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Thursday, November 7, 2024 at 4:30 pm ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2024.
A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.
Q4 Investor Conferences
Management will also be participating in the following investor healthcare conferences:
- The Guggenheim Inaugural Global Healthcare Conference in a fireside chat featuring Paul J. Diaz, President and CEO, on Wednesday, November 13, 2024 at 3:30 pm ET.
- The 6th Annual Wolfe Research Healthcare Conference in a fireside chat featuring Scott Leffler, Chief Financial Officer, and Sam Raha, Chief Operating Officer, on Wednesday, November 20, 2024 at 3:20 pm ET.
Live and archived webcasts of all presentations can be viewed at investor.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
FAQ
When will Myriad Genetics (MYGN) release Q3 2024 earnings?
Which investor conferences will Myriad Genetics (MYGN) attend in November 2024?
How can investors access Myriad Genetics (MYGN) Q3 2024 earnings call?
